Managing the Risks of Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Current and Emerging Therapies

Managing the Risks of Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Current and Emerging Therapies is organized by Med Learning Group.

Dates:
Release Date: Oct 11, 2019
Expiration Date: Oct 11, 2020

Accreditation:
Credit Designation Statement:
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Credit Information:
Purpose: This program would be beneficial for nurses involved in the treatment and management of patients with Metastatic Hormone-Sensitive Prostate Cancer.
Credits: 1.0 ANCC Contact Hour.

CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

Description:
This enduring activity will cover the treatment and management of patients with metastatic hormone-sensitive prostate cancer.

Objectives:
On completing the program, attendees should be able to:
• Discuss the metabolic and cardiovascular changes observed with androgen deprivation therapy
• Describe recommended management strategies to minimize cardiovascular risks in patients with prostate cancer
• Evaluate the efficacy and safety of current and emerging treatment options for metastatic hormone-sensitive prostate cancer

Additional details will be posted as soon as information is available.